NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|309747091|ref|NP_001185470|]
View 

endoplasmic reticulum aminopeptidase 1 isoform b precursor [Homo sapiens]

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176184)

M1 family metallopeptidase containing an ERAP1-like C-terminal domain with HEAT-like repeats; similar to aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
61-526 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


:

Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 635.39  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  61 VHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGErlSEEPLQVLEHPRQEQIALLAPEPLL 140
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGS--GIIEVTVVTDEETEFLTITLDETLP 78
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 141 VGLPYTVVIHYAGNLSETFHGFYKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMP 220
Cdd:cd09601   79 PGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSNMP 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 221 LVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIP 300
Cdd:cd09601  159 PVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIP 238
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 301 YPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAK 380
Cdd:cd09601  239 YPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFAT 318
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 381 FMEFVSVSVTHPELKVGDYFF-GKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKS 459
Cdd:cd09601  319 YMEYLAVDKLFPEWNMWDQFVvDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVFRK 398
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 309747091 460 GIVQYLQKHSYKNTKNEDLWDSMASICPTDgvkgmdgfcsrsqhssssshwhqEGVDVKTMMNTWTL 526
Cdd:cd09601  399 GLRKYLKKHAYGNATTDDLWEALQEASGES-----------------------KPLDVKEIMDSWTL 442
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
597-916 1.48e-87

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


:

Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 282.63  E-value: 1.48e-87
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  597 WIKFNVGMNGYYIVHYEDDGWDSLTGLLKgtHTAVSSNDRASLINNAFQLVSIGKLSIEKALDLSLYLKHETEIMPVFQG 676
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLL--SKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  677 LNELIPMYKLMEKrdmNEVETQFKAFLIRLLRDLIDKQTWTDEG--SVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKW 754
Cdd:pfam11838  79 LSQLSTLRSLLSA---DPEYEALKAFLRKLLSPLAEKLGWEAPPgeSHLDRQLRALLLSAACSAGDPECVAEAKKLFDAW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  755 KesNGNLSLPVDVTLAVFAVGAQ--STEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEF 832
Cdd:pfam11838 156 L--DGDDAIPPDLRWAVYCAAVAngGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDL 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  833 PQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFElGSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQlRCVQQTI 912
Cdd:pfam11838 234 RAVIAGLASNPAGRDLAWDFVKENWDALVKRLG-GGSSLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLR-RALAQAL 311

                  ....
gi 309747091  913 ETIE 916
Cdd:pfam11838 312 ETIR 315
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
61-526 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 635.39  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  61 VHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGErlSEEPLQVLEHPRQEQIALLAPEPLL 140
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGS--GIIEVTVVTDEETEFLTITLDETLP 78
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 141 VGLPYTVVIHYAGNLSETFHGFYKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMP 220
Cdd:cd09601   79 PGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSNMP 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 221 LVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIP 300
Cdd:cd09601  159 PVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIP 238
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 301 YPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAK 380
Cdd:cd09601  239 YPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFAT 318
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 381 FMEFVSVSVTHPELKVGDYFF-GKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKS 459
Cdd:cd09601  319 YMEYLAVDKLFPEWNMWDQFVvDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVFRK 398
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 309747091 460 GIVQYLQKHSYKNTKNEDLWDSMASICPTDgvkgmdgfcsrsqhssssshwhqEGVDVKTMMNTWTL 526
Cdd:cd09601  399 GLRKYLKKHAYGNATTDDLWEALQEASGES-----------------------KPLDVKEIMDSWTL 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
60-600 5.87e-126

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 394.40  E-value: 5.87e-126
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  60 PVHYDLLIHANLTTLTFWGTTKVEITASQP-TSTIILHSHHLQISRATLRKgagerlseEPLQVLEHPrqEQIALLAPEP 138
Cdd:COG0308   17 VTHYDLDLDLDPATTRLSGTATITFTATEApLDSLVLDLKGLEVTSVTVDG--------KPLDFTRDG--ERLTITLPKP 86
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 139 LLVGLPYTVVIHYAGNLSETFHGFYKSTYrtkEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISN 218
Cdd:COG0308   87 LAPGETFTLEIEYSGKPSNGGEGLYRSGD---PPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGWVAVSN 163
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 219 MPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFS 298
Cdd:COG0308  164 GNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRMLDFFEELFG 243
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 299 IPYPLPKQDLAAIPDFQSGAMENWGLTTYRESaLLFDaEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGF 378
Cdd:COG0308  244 VPYPFDKYDQVAVPDFNFGAMENQGLVTFGEK-VLAD-ETATDADYERRESVIAHELAHQWFGNLVTCADWDDLWLNEGF 321
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 379 AKFMEFVSVSVTHPELKVGDYFFGKCFD-AMEVDALNSSHPVStpVENPAQIREMFDDVSYDKGACILNMLREYLSADAF 457
Cdd:COG0308  322 ATYMEQLFSEDLYGKDAADRIFVGALRSyAFAEDAGPNAHPIR--PDDYPEIENFFDGIVYEKGALVLHMLRTLLGDEAF 399
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 458 KSGIVQYLQKHSYKNTKNEDLWDSMASICptdgvkgmdgfcsrsqhssssshwhqeGVDVKTMMNTWTLQKGFPLITITV 537
Cdd:COG0308  400 RAGLRLYFARHAGGNATTEDFLAALEEAS---------------------------GRDLSAFFDQWLYQAGLPTLEVEY 452
                        490       500       510       520       530       540
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 309747091 538 RGRN-----VHMKQEhymkgsdgaPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVlILPEEVEWIKF 600
Cdd:COG0308  453 EYDAdgkvtLTLRQT---------PPRPHPFHIPLEVGLLGGKLTARTVLLDGEQT-ELVAKPDPVLL 510
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
281-482 1.16e-92

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 292.27  E-value: 1.16e-92
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  281 YALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWF 360
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  361 GNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKV-GDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYD 439
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIwEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|...
gi 309747091  440 KGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSM 482
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDAL 203
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
597-916 1.48e-87

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 282.63  E-value: 1.48e-87
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  597 WIKFNVGMNGYYIVHYEDDGWDSLTGLLKgtHTAVSSNDRASLINNAFQLVSIGKLSIEKALDLSLYLKHETEIMPVFQG 676
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLL--SKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  677 LNELIPMYKLMEKrdmNEVETQFKAFLIRLLRDLIDKQTWTDEG--SVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKW 754
Cdd:pfam11838  79 LSQLSTLRSLLSA---DPEYEALKAFLRKLLSPLAEKLGWEAPPgeSHLDRQLRALLLSAACSAGDPECVAEAKKLFDAW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  755 KesNGNLSLPVDVTLAVFAVGAQ--STEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEF 832
Cdd:pfam11838 156 L--DGDDAIPPDLRWAVYCAAVAngGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDL 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  833 PQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFElGSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQlRCVQQTI 912
Cdd:pfam11838 234 RAVIAGLASNPAGRDLAWDFVKENWDALVKRLG-GGSSLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLR-RALAQAL 311

                  ....
gi 309747091  913 ETIE 916
Cdd:pfam11838 312 ETIR 315
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
180-489 2.91e-64

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 232.76  E-value: 2.91e-64
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  180 TQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNmPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSK 259
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISN-SRETDVTPEPADRRWEFPETPKLSTYLTAVAAGPYHSVQD 200
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  260 iTKSGVKVSVYAVPD--KINQADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESaLLFDAE 337
Cdd:TIGR02412 201 -ESRSYPLGIYARRSlaQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAEN-FLHRAE 278
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  338 kSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFME-FVSVSVT-HPELKVGDYFFGKCFdAMEVDALNS 415
Cdd:TIGR02412 279 -ATRAEKENRAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGtLASAEATeYTDAWTTFAAQGKQW-AYEADQLPT 356
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 309747091  416 SHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTD 489
Cdd:TIGR02412 357 THPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKASGRD 430
pepN PRK14015
aminopeptidase N; Provisional
245-468 6.45e-09

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 59.76  E-value: 6.45e-09
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 245 YLVAFIISDFESVSK--ITKSG--VKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYplpkqDL-----AAIPDFQ 315
Cdd:PRK14015 190 YLFALVAGDLDVLEDtfTTRSGreVALEIYVEPGNLDKCDHAMDSLKKSMKWDEERFGLEY-----DLdifmiVAVDDFN 264
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 316 SGAMENWGLTTYRESALLFDAEksSASSK--LGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKF--MEF------- 384
Cdd:PRK14015 265 MGAMENKGLNIFNSKYVLADPE--TATDAdyERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFrdQEFsadlgsr 342
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 385 -------VSVSVTH--PElkvgdyffgkcfDA--MevdalnsSHPVstpveNPAQIREM--FDDVS-YDKGACILNMLRE 450
Cdd:PRK14015 343 avkriedVRVLRAAqfAE------------DAgpM-------AHPV-----RPDSYIEInnFYTATvYEKGAEVIRMLHT 398
                        250
                 ....*....|....*...
gi 309747091 451 YLSADAFKSGIVQYLQKH 468
Cdd:PRK14015 399 LLGEEGFRKGMDLYFERH 416
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
61-526 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 635.39  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  61 VHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGErlSEEPLQVLEHPRQEQIALLAPEPLL 140
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGS--GIIEVTVVTDEETEFLTITLDETLP 78
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 141 VGLPYTVVIHYAGNLSETFHGFYKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMP 220
Cdd:cd09601   79 PGENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSNMP 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 221 LVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIP 300
Cdd:cd09601  159 PVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIP 238
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 301 YPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAK 380
Cdd:cd09601  239 YPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFAT 318
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 381 FMEFVSVSVTHPELKVGDYFF-GKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKS 459
Cdd:cd09601  319 YMEYLAVDKLFPEWNMWDQFVvDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVFRK 398
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 309747091 460 GIVQYLQKHSYKNTKNEDLWDSMASICPTDgvkgmdgfcsrsqhssssshwhqEGVDVKTMMNTWTL 526
Cdd:cd09601  399 GLRKYLKKHAYGNATTDDLWEALQEASGES-----------------------KPLDVKEIMDSWTL 442
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
61-484 2.22e-175

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 515.07  E-value: 2.22e-175
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  61 VHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGERLSEEplqvleHPRQEQIALLAPEPll 140
Cdd:cd09595    1 YHYDLDLDVDFTTKTLNGTETLTVDASQVGRELVLDLVGLTIHSVSVNGAAVDFGERE------HYDGEKLTIPGPKP-- 72
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 141 VGLPYTVVIHYAGNLSETFHGFYKstyRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMP 220
Cdd:cd09595   73 PGQTFTVRISFEAKPSKNLLGWLW---EQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKDLLASNGA 149
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 221 LVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKS--GVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFS 298
Cdd:cd09595  150 LVGEETGANGRKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSqpRVGLSVYSEPLQVDQAQYAFDATRAALAWFEDYFG 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 299 IPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEksSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGF 378
Cdd:cd09595  230 GPYPLPKYDLLAVPDFNSGAMENPGLITFRTTYLLRSKV--TDTGARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEGF 307
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 379 AKFMEFVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFK 458
Cdd:cd09595  308 AVYYENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTSTPVRSPADPDVAYDGVTYAKGALVLRMLEELVGEEAFD 387
                        410       420
                 ....*....|....*....|....*.
gi 309747091 459 SGIVQYLQKHSYKNTKNEDLWDSMAS 484
Cdd:cd09595  388 KGVQAYFNRHKFKNATTDDFIDALEE 413
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
60-600 5.87e-126

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 394.40  E-value: 5.87e-126
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  60 PVHYDLLIHANLTTLTFWGTTKVEITASQP-TSTIILHSHHLQISRATLRKgagerlseEPLQVLEHPrqEQIALLAPEP 138
Cdd:COG0308   17 VTHYDLDLDLDPATTRLSGTATITFTATEApLDSLVLDLKGLEVTSVTVDG--------KPLDFTRDG--ERLTITLPKP 86
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 139 LLVGLPYTVVIHYAGNLSETFHGFYKSTYrtkEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISN 218
Cdd:COG0308   87 LAPGETFTLEIEYSGKPSNGGEGLYRSGD---PPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGWVAVSN 163
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 219 MPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFS 298
Cdd:COG0308  164 GNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRMLDFFEELFG 243
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 299 IPYPLPKQDLAAIPDFQSGAMENWGLTTYRESaLLFDaEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGF 378
Cdd:COG0308  244 VPYPFDKYDQVAVPDFNFGAMENQGLVTFGEK-VLAD-ETATDADYERRESVIAHELAHQWFGNLVTCADWDDLWLNEGF 321
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 379 AKFMEFVSVSVTHPELKVGDYFFGKCFD-AMEVDALNSSHPVStpVENPAQIREMFDDVSYDKGACILNMLREYLSADAF 457
Cdd:COG0308  322 ATYMEQLFSEDLYGKDAADRIFVGALRSyAFAEDAGPNAHPIR--PDDYPEIENFFDGIVYEKGALVLHMLRTLLGDEAF 399
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 458 KSGIVQYLQKHSYKNTKNEDLWDSMASICptdgvkgmdgfcsrsqhssssshwhqeGVDVKTMMNTWTLQKGFPLITITV 537
Cdd:COG0308  400 RAGLRLYFARHAGGNATTEDFLAALEEAS---------------------------GRDLSAFFDQWLYQAGLPTLEVEY 452
                        490       500       510       520       530       540
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 309747091 538 RGRN-----VHMKQEhymkgsdgaPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVlILPEEVEWIKF 600
Cdd:COG0308  453 EYDAdgkvtLTLRQT---------PPRPHPFHIPLEVGLLGGKLTARTVLLDGEQT-ELVAKPDPVLL 510
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
281-482 1.16e-92

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 292.27  E-value: 1.16e-92
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  281 YALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWF 360
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  361 GNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKV-GDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYD 439
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIwEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|...
gi 309747091  440 KGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSM 482
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDAL 203
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
61-489 4.65e-92

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 299.04  E-value: 4.65e-92
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  61 VHYDLLIhaNLTTL--TFWGTTKVEITASQPTSTIILHSHHLQISRATLrkgagerlSEEPLQVlEHPRQEQIALlapEP 138
Cdd:cd09602   16 VSYDLDL--DLTEGaeTFRGTVTIRFTLREPGASLFLDFRGGEVKSVTL--------NGRPLDP-SAFDGERITL---PG 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 139 LLVGLPYTVVIHYAG---NLSETFHGF----YKSTYrtkegelriLaSTQFEPTAARMAFPCFDEPAFKASFSIKIRREP 211
Cdd:cd09602   82 LLKAGENTVVVEFTApysSDGEGLHRFvdpaDGETY---------L-YTLFEPDDARRVFPCFDQPDLKATFTLTVTAPA 151
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 212 RHLAISNMPLVKSVTVAEGLIEdHFDVTVKMSTYLVAFIISDFESVSKiTKSGVKVSVYA---VPDKINQADYALDAAVT 288
Cdd:cd09602  152 DWTVISNGPETSTEEAGGRKRW-RFAETPPLSTYLFAFVAGPYHRVED-EHDGIPLGLYCresLAEYERDADEIFEVTKQ 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 289 LLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFdaEKSSASSKLGITMTVAHELAHQWFGNLVTMEW 368
Cdd:cd09602  230 GLDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFR--EEPTRAQRLRRANTILHEMAHMWFGDLVTMKW 307
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 369 WNDLWLNEGFAKFME-FVSVSVT-HPELKVGDYFFGKCFdAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILN 446
Cdd:cd09602  308 WDDLWLNESFADFMAaKALAEATpFTDAWLTFLLRRKPW-AYRADQLPTTHPIAQDVPDLEAAGSNFDGITYAKGASVLK 386
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|...
gi 309747091 447 MLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTD 489
Cdd:cd09602  387 QLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRD 429
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
597-916 1.48e-87

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 282.63  E-value: 1.48e-87
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  597 WIKFNVGMNGYYIVHYEDDGWDSLTGLLKgtHTAVSSNDRASLINNAFQLVSIGKLSIEKALDLSLYLKHETEIMPVFQG 676
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLL--SKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  677 LNELIPMYKLMEKrdmNEVETQFKAFLIRLLRDLIDKQTWTDEG--SVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKW 754
Cdd:pfam11838  79 LSQLSTLRSLLSA---DPEYEALKAFLRKLLSPLAEKLGWEAPPgeSHLDRQLRALLLSAACSAGDPECVAEAKKLFDAW 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  755 KesNGNLSLPVDVTLAVFAVGAQ--STEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEF 832
Cdd:pfam11838 156 L--DGDDAIPPDLRWAVYCAAVAngGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDL 233
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  833 PQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFElGSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQlRCVQQTI 912
Cdd:pfam11838 234 RAVIAGLASNPAGRDLAWDFVKENWDALVKRLG-GGSSLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLR-RALAQAL 311

                  ....
gi 309747091  913 ETIE 916
Cdd:pfam11838 312 ETIR 315
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
62-482 9.22e-75

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 251.35  E-value: 9.22e-75
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  62 HYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATL--RKGAGERLSEEPLQvlehprqeqIALlaPEPL 139
Cdd:cd09603    5 HYDLDLDYDPATKSLSGTATITFRATQDLDSLQLDLVGLTVSSVTVdgVPAAFFTHDGDKLV---------ITL--PRPL 73
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 140 LVGLPYTVVIHYAGN--LSETFHGFYKSTYRTKEGelrilASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAIS 217
Cdd:cd09603   74 AAGETFTVTVRYSGKprPAGYPPGDGGGWEEGDDG-----VWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTVVS 148
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 218 NMPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYF 297
Cdd:cd09603  149 NGRLVSTTTNGGGTTTWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEELF 228
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 298 sIPYPLPKQDLAAIPDFqSGAMENWGLTTYRESALLFDaekssasskLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEG 377
Cdd:cd09603  229 -GPYPFEKYGQVVVPDL-GGGMEHQTATTYGNNFLNGD---------RGSERLIAHELAHQWFGDSVTCADWADIWLNEG 297
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 378 FAKFMEFVSVsvthpelkvgDYFFGK-CFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADA 456
Cdd:cd09603  298 FATYAEWLWS----------EHKGGAdAYRAYLAGQRQDYLNADPGPGRPPDPDDLFDRDVYQKGALVLHMLRNLLGDEA 367
                        410       420
                 ....*....|....*....|....*.
gi 309747091 457 FKSGIVQYLQKHSYKNTKNEDLWDSM 482
Cdd:cd09603  368 FFAALRAYLARYAHGNVTTEDFIAAA 393
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
180-489 2.91e-64

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 232.76  E-value: 2.91e-64
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  180 TQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNmPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSK 259
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISN-SRETDVTPEPADRRWEFPETPKLSTYLTAVAAGPYHSVQD 200
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  260 iTKSGVKVSVYAVPD--KINQADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESaLLFDAE 337
Cdd:TIGR02412 201 -ESRSYPLGIYARRSlaQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAEN-FLHRAE 278
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  338 kSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFME-FVSVSVT-HPELKVGDYFFGKCFdAMEVDALNS 415
Cdd:TIGR02412 279 -ATRAEKENRAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGtLASAEATeYTDAWTTFAAQGKQW-AYEADQLPT 356
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 309747091  416 SHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTD 489
Cdd:TIGR02412 357 THPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAKASGRD 430
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
60-246 3.81e-51

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 177.92  E-value: 3.81e-51
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091   60 PVHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGERLSEEPLQVLEhPRQEQIALLAPEPL 139
Cdd:pfam17900   2 PEHYDLDLKIDLKNFTFSGSVTITLQLNNATNVIVLHASDLTIRSISLSDEVTSDGVPADFTEDQ-KDGEKLTIVLPETL 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  140 LVGLPYTVVIHYAGNLSETFHGFYKSTYrTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNM 219
Cdd:pfam17900  81 NQTGPYTLEIEYSGELNDSMTGFYRSTY-TDNGEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTALSNM 159
                         170       180
                  ....*....|....*....|....*..
gi 309747091  220 PLVKSVTVAEGLIEDHFDVTVKMSTYL 246
Cdd:pfam17900 160 PVIASEPLENGWVITTFEQTPKMSTYL 186
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
55-471 5.15e-30

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 124.49  E-value: 5.15e-30
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  55 PEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQP-TSTIILHSHHLQISRATLRkgagerlSEEPLQVLEHPRQE---- 129
Cdd:cd09599    8 YDEVRTTHLDLDLTVDFDKKTISGSATLTLEVLQDgADELVLDTRDLDISSVTVN-------GGKELKFELGPRDPvlgs 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 130 --QIALlaPEPLLVGLPYTVVIHYAgnlsetfhgfykstyrTKEGelrilAS-------------------TQFEPTAAR 188
Cdd:cd09599   81 alTITL--PSPLAKGDTFKVKIEYS----------------TTPQ-----ATalqwltpeqtagkkhpylfTQCQAIHAR 137
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 189 MAFPCFDEPAFKASFSIKIRrEPRHL-----AISnmplvKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVsKItks 263
Cdd:cd09599  138 SLFPCQDTPSVKSTYSATVT-VPKGLtalmsALR-----TGEKEEAGTGTYTFEQPVPIPSYLIAIAVGDLESR-EI--- 207
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 264 GVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSiPYP--------LPkqdlaaiPDFQSGAMENWGLT--TyreSALL 333
Cdd:cd09599  208 GPRSGVWAEPSVVDAAAEEFADTEKFLKAAEKLYG-PYVwgrydllvLP-------PSFPYGGMENPCLTfaT---PTLI 276
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 334 FDaEKSSASsklgitmTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPElkvgDYFfgkCFDAM----- 408
Cdd:cd09599  277 AG-DRSLVD-------VIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYLERRILERLYGE----EYR---QFEAIlgwkd 341
                        410       420       430       440       450       460       470
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 309747091 409 ---EVDALNSSHP-----VSTPVENPaqiremfDD----VSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYK 471
Cdd:cd09599  342 lqeSIKEFGEDPPytllvPDLKGVDP-------DDafssVPYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQ 409
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
53-489 9.76e-30

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 123.39  E-value: 9.76e-30
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  53 RLPEYVIP-VHYDLLIHANLTTLTfwGTTKVE-ITASQPTSTIILHSHHLQISRATLrkgAGERLSEEPLQVLEhprqEQ 130
Cdd:cd09600    3 KPPDFLIDhVDLDFDLDDDETIVT--SRLRVRrNPDSGEGAPLVLDGEDLELLSVKI---DGKPLSPSDYTLDE----EG 73
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 131 IALLAPEPLLVgLPYTVVIHYAGNLSETfhGFYKSTyrtkegelRILaSTQFEPTAARMAFPCFDEPAFKASFSIKIRRE 210
Cdd:cd09600   74 LTIKNVPDRFV-LEIEVRINPAANTSLE--GLYKSG--------GIL-CTQCEAEGFRRITYFPDRPDVMSKFTVTIEAD 141
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 211 PRHLAI--SNMPLVKSVTVAEGLiedHF----DVTVKMStYLVAFIISDFESVSK--ITKSG--VKVSVYAVPDKINQAD 280
Cdd:cd09600  142 KEKYPVllSNGNLIEEGELPNGR---HFavweDPFPKPS-YLFALVAGDLGSVEDtfTTKSGrkVKLRIYVEPGNEDKCH 217
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 281 YALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWF 360
Cdd:cd09600  218 HAMESLKKAMKWDEERFGLEYDLDLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWT 297
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 361 GNLVTMEWWNDLWLNEGFAKF--MEFvSVSVTHPELK-VGDYFFGKCFDAMEvDALNSSHPVstpveNPAQIREM--FDD 435
Cdd:cd09600  298 GNRVTCRDWFQLSLKEGLTVFrdQEF-SADMNSRAVKrIEDVRRLRSAQFPE-DAGPMAHPI-----RPDSYIEInnFYT 370
                        410       420       430       440       450
                 ....*....|....*....|....*....|....*....|....*....|....*
gi 309747091 436 VS-YDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTD 489
Cdd:cd09600  371 VTvYEKGAEVIRMLHTLLGEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRD 425
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
248-489 2.34e-29

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 122.38  E-value: 2.34e-29
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 248 AFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFsIPYPLPKQDLAAiPDFQSGAMENWGLTTy 327
Cdd:cd09604  205 AWAASPDFVVDAATVDGVTVNVYYLPENAEAAERALEYAKDALEFFSEKF-GPYPYPELDVVQ-GPFGGGGMEYPGLVF- 281
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 328 resallfdAEKSSASSKLGITMTVAHELAHQWFGNLVTmewwND----LWLNEGFAKFMEFVSVSVTHPELKVGDYFFgk 403
Cdd:cd09604  282 --------IGSRLYDPKRSLEGVVVHEIAHQWFYGIVG----NDerrePWLDEGLATYAESLYLEEKYGKEAADELLG-- 347
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 404 cFDAMEVDALNSSHPVSTPVENPAQIREMFDdVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMA 483
Cdd:cd09604  348 -RRYYRAYARGPGGPINLPLDTFPDGSYYSN-AVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAE 425

                 ....*.
gi 309747091 484 SICPTD 489
Cdd:cd09604  426 EVSGKD 431
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
55-490 2.30e-22

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 102.55  E-value: 2.30e-22
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091   55 PEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQP-TSTIILHSHHLQISRATLRKgagerlSEEPLQVLEhpRQEQIAl 133
Cdd:TIGR02411   8 YKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDnLNKLVLDTSYLDIQKVTING------LPADFAIGE--RKEPLG- 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  134 lapEPLLVGLP--------YTVVIHYAGNLSETFHGFYKSTyRTKEGELRILAStQFEPTAARMAFPCFDEPAFKASFSI 205
Cdd:TIGR02411  79 ---SPLTISLPiatskndeFVLNISFSTTPKCTALQWLNPE-QTSGKKHPYLFS-QCQAIHARSLFPCQDTPSVKSTYTA 153
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  206 KIRreprhlaiSNMPLVKSVTVAEGLIEDH----FDVTVKMSTYLVAFIISDFESvskiTKSGVKVSVYAVPDKINQADY 281
Cdd:TIGR02411 154 EVE--------SPLPVLMSGIRDGETSNDPgkylFKQKVPIPAYLIAIASGDLAS----APIGPRSTVYSEPEQLEKCQY 221
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  282 ALDAAV-TLLEFYEDyFSIPYPLPKQDLAAIPD-FQSGAMENWGLTTyrESALLFDAEKSSASsklgitmTVAHELAHQW 359
Cdd:TIGR02411 222 EFENDTeKFIKTAED-LIFPYEWGQYDLLVLPPsFPYGGMENPNLTF--ATPTLIAGDRSNVD-------VIAHELAHSW 291
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091  360 FGNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKvgdyffgKCFDAM--------EVDALNSSHPVSTPVEN--PAQI 429
Cdd:TIGR02411 292 SGNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGEKT-------RHFSALigwgdlqeSVKTLGETPEFTKLVVDlkDNDP 364
                         410       420       430       440       450       460
                  ....*....|....*....|....*....|....*....|....*....|....*....|..
gi 309747091  430 REMFDDVSYDKGACILNMLREYLSADA-FKSGIVQYLQKHSYKNTKNEDLWDSMASICPTDG 490
Cdd:TIGR02411 365 DDAFSSVPYEKGFNFLFYLEQLLGGPAeFDPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKK 426
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
183-382 2.85e-09

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 60.71  E-value: 2.85e-09
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 183 EPTAARMAFPCFDEPAFKASFSIKIRRePRHLA-ISNMPLVKSVT------------------VAEG-LIED-------- 234
Cdd:cd09839  172 LPGSARCWFPCVDSLWERCTWELEITV-PRTLGdAGRPPLAGSKEdeddddlteedkelemvvVCSGdLVEQvvhpedps 250
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 235 ----HFDVTVKMSTYLVAFIISDFESVS-----------KITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSi 299
Cdd:cd09839  251 kktfSFSLSNPTSAQHIGFAVGPFEIVPlpefreseeddKLGSSAVEVTGFCLPGRLEELRNTCSFLHKAMDFFEEEYG- 329
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 300 PYPLP--KQ----DLAAipDFQSGAmenwGLTTYrESALLFDAEkssassklgI-------TMTVAHELAHQWFGNLVTM 366
Cdd:cd09839  330 SYPFSsyKQvfvdDLPE--DVSSFA----SLSIC-SSRLLYPPD---------IidqayetRRKLAHALASQWFGINIIP 393
                        250
                 ....*....|....*.
gi 309747091 367 EWWNDLWLNEGFAKFM 382
Cdd:cd09839  394 KTWSDTWLVIGIAGYM 409
pepN PRK14015
aminopeptidase N; Provisional
245-468 6.45e-09

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 59.76  E-value: 6.45e-09
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 245 YLVAFIISDFESVSK--ITKSG--VKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYplpkqDL-----AAIPDFQ 315
Cdd:PRK14015 190 YLFALVAGDLDVLEDtfTTRSGreVALEIYVEPGNLDKCDHAMDSLKKSMKWDEERFGLEY-----DLdifmiVAVDDFN 264
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 316 SGAMENWGLTTYRESALLFDAEksSASSK--LGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKF--MEF------- 384
Cdd:PRK14015 265 MGAMENKGLNIFNSKYVLADPE--TATDAdyERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFrdQEFsadlgsr 342
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 385 -------VSVSVTH--PElkvgdyffgkcfDA--MevdalnsSHPVstpveNPAQIREM--FDDVS-YDKGACILNMLRE 450
Cdd:PRK14015 343 avkriedVRVLRAAqfAE------------DAgpM-------AHPV-----RPDSYIEInnFYTATvYEKGAEVIRMLHT 398
                        250
                 ....*....|....*...
gi 309747091 451 YLSADAFKSGIVQYLQKH 468
Cdd:PRK14015 399 LLGEEGFRKGMDLYFERH 416
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
290-384 1.57e-05

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 44.78  E-value: 1.57e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 309747091 290 LEFYEDYFSI----PYPLPKQDLAAIPDFQSGAMENwGLTTYrESALLFDAEKSSASSklGITMTVAHELAHQWFGNLVT 365
Cdd:cd09594    8 YKYYEELLGRtsfrYPVSPIYSLLVYPAYVEVNAYN-AMWIP-STNIFYGAGILDTLS--GTIDVLAHELTHAFTGQFSN 83
                         90       100
                 ....*....|....*....|
gi 309747091 366 MEW-WNDLWLNEGFAKFMEF 384
Cdd:cd09594   84 LMYsWSSGWLNEGISDYFGG 103
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH